SCHEMBL709378

SCHEMBL709378

O=CCc1cccc2c1C(=O)NC2=O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.43
KDM4E B2RXH2 3/20 0.41
ALDH1A1 P00352 3/20 0.41
GAA P10253 2/20 0.41
HPGD P15428 1/20 0.41
HSD17B10 Q99714 1/20 0.41
PARP1 P09874 5/20 0.41
CASP3 P42574 6/20 0.38
CASP7 P55210 2/20 0.38
CASP2 P42575 1/20 0.38
CASP6 P55212 1/20 0.38
CASP8 Q14790 1/20 0.38
GSK3A P49840 1/20 0.37
CDK5 Q00535 1/20 0.37
CDK5R1 Q15078 1/20 0.37
MEN1 O00255 2/20 0.35
POLB P06746 2/20 0.35
KMT2A Q03164 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
RGS12 O14924 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16863190 0.87 PARP1 (0.47) GSK3BKDM4EALDH1A1GAAHPGD
SCHEMBL170914 0.84 GABRA1 (0.49) GSK3BKDM4EALDH1A1GAAHPGD
Ammonia Solution, Strong SCHEMBL3259478 0.83 GABRA1 (0.47) GSK3BKDM4EALDH1A1GAAHPGD
SCHEMBL4975651 0.81 PARP1 (0.42) GSK3BKDM4EALDH1A1GAAHPGD
SCHEMBL2312958 0.81 PARP1 (0.42) GSK3BKDM4EALDH1A1GAAHPGD
SCHEMBL11615870 0.81 KDM4E (0.42) GSK3BKDM4EALDH1A1GAAHPGD
SCHEMBL10416488 0.81 PARP1 (0.42) GSK3BKDM4EALDH1A1GAAHPGD
SCHEMBL9621417 0.81 KDM4E (0.36) GSK3BKDM4EALDH1A1GAAHPGD
SCHEMBL5970012 0.81 GSK3B (0.50) GSK3BKDM4EALDH1A1GAAHPGD
SCHEMBL10713059 0.81 GSK3B (0.50) GSK3BKDM4EALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087635-A1 DIHYDRO BENZOXAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2026-04-30 WO disclosed
CN-115667280-A Method and reagent for synthesizing nucleoside and analogue thereof 西蒙弗雷泽大学 2023-01-31 CN disclosed
US-8293715-B2 10a-Azalide compound crosslinked at 10a- and 12-positions TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-10-23 US disclosed
US-8124744-B2 Macrolide derivatives TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-02-28 US disclosed
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS TAISHO PHARMACEUTICAL CO., LTD. (JP) 2011-09-29 US disclosed
EP-2177526-A1 10A-AZALIDE COMPOUND CROSSLINKED AT POSITION-10A AND POSITION-12 Taisho Pharmaceutical Co. Ltd. (JP) 2010-04-21 EP disclosed
EP-2077271-A1 MACROLIDE DERIVATIVE TAISHO PHARMACEUTICAL CO., LTD (JP) 2009-07-08 EP disclosed
US-20090076253-A1 MACROLIDE DERIVATIVES TAISHO PHARMACEUTICAL CO., LTD (JP) 2009-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237784-A1 10A-AZALIDE COMPOUND CROSSLINKED AT 10A- AND 12-POSITIONS DCLRE1A, AZI2, CHD9 GSK3B 3724/4885KDM4E 64/4885ALDH1A1 2376/4885
US-20090076253-A1 MACROLIDE DERIVATIVES MMP9, MMP2, MMP11 GSK3B 1308/4885KDM4E 4654/4885ALDH1A1 1697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.